EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial

Gail M Gauvreau iD, Roma Sehmi iD, J Mark FitzGerald, Richard Leigh iD, Donald W Cockcroft, Beth E Davis, Irvin Mayers, Louis-Philippe Boulet, Dhuha Al-Sajee, Brittany M Salter, Ruth P Cusack, Terence Ho iD und 16 weitere

European Respiratory Journal · 2024

DOI: 10.1183/13993003.00512-2024 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Gail M Gauvreau und 27 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Eosinophils, Anti-Asthmatic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benralizumab induces rapid and near-complete depletion of eosinophils from blood and lung tissue. We investigated whether benralizumab could attenuate the allergen-induced late asthmatic response (LAR) in participants with allergic asthma.

Methods

Participants with allergic asthma who demonstrated increased sputum eosinophils and LAR at screening were randomised to benralizumab 30 mg or matched placebo given every 4 weeks for 8 weeks (3 doses). Allergen challenges were performed at weeks 9 and 12 when blood, sputum, bone marrow and bronchial tissue eosinophils and LAR were assessed.

Results

46 participants (mean age 30.9 years) were randomised to benralizumab (n=23) or placebo (n=23). Eosinophils were significantly reduced in the benralizumab group compared with placebo in blood at 4 weeks and sputum and bone marrow at 9 weeks after treatment initiation. At 7 h after an allergen challenge at week 9, sputum eosinophilia was significantly attenuated in the benralizumab group compared to placebo (least squares mean difference −5.81%, 95% CI −10.69– −0.94%; p=0.021); however, the LAR was not significantly different (least squares mean difference 2.54%, 95% CI 3.05–8.12%; p=0.363). Adverse events were reported for seven (30.4%) and 14 (60.9%) participants in the benralizumab and placebo groups, respectively.

Conclusion

Benralizumab administration over 8 weeks resulted in a significant attenuation of blood, bone marrow and sputum eosinophilia in participants with mild allergic asthma; however, there was no change in the LAR, suggesting that eosinophils alone are not a key component of allergen-induced bronchoconstriction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedEosinophilsAnti-Asthmatic AgentsSputumHumansMaleFemaleDouble-Blind MethodAdultMiddle AgedTreatment OutcomeYoung AdultAllergensEosinophilia

Substanzen

benralizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsAllergens

Autor:innen und Institutionen

  • Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca.
  • Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
  • Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
  • J.M. Fitzgerald passed away in early 2022; all authors agreed to his inclusion as an author.
  • Cumming School of Medicine, Calgary, AB, Canada.
  • University of Saskatchewan, Saskatoon, SK, Canada.

ORCID-Profile: Gail M Gauvreau, Roma Sehmi, Richard Leigh, Terence Ho, Imran Satia, Patrick D Mitchell, Paul M O'Byrne

Förderung

  • AstraZeneca

Zitieren

APA

Gauvreau, G. M., Sehmi, R., FitzGerald, J. M., Leigh, R., Cockcroft, D. W., Davis, B. E., Mayers, I., Boulet, L. P., Al-Sajee, D., Salter, B. M., Cusack, R. P., Ho, T., Whetstone, C. E., Alsaji, N., Satia, I., Killian, K. J., Mitchell, P. D., Magee, I. P., Bergeron, C., …, & O'Byrne, P. M. (2024). Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial. European Respiratory Journal. https://doi.org/10.1183/13993003.00512-2024

Vancouver

Gauvreau GM, Sehmi R, FitzGerald JM, Leigh R, Cockcroft DW, Davis BE, et al. Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial. European Respiratory Journal. 2024. doi:10.1183/13993003.00512-2024

BibTeX
@article{Gauvreau2024,
  author = {Gauvreau, Gail M and Sehmi, Roma and FitzGerald, J Mark and Leigh, Richard and Cockcroft, Donald W and Davis, Beth E and Mayers, Irvin and Boulet, Louis-Philippe and Al-Sajee, Dhuha and Salter, Brittany M and Cusack, Ruth P and Ho, Terence and Whetstone, Christiane E and Alsaji, Nadia and Satia, Imran and Killian, Kieran J and Mitchell, Patrick D and Magee, Iain P and Bergeron, Celine and Bhutani, Mohit and Werkström, Viktoria and Durżyński, Tomasz and Shoemaker, Kathryn and Katial, Rohit K and Jison, Maria and Newbold, Paul and McCrae, Christopher and O'Byrne, Paul M},
  title = {Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.00512-2024}
}
Kostenlos starten →